BMI View: The value of the Dutch pharmaceutical market will see yet another year of contraction in 2016,
although we expect a return to growth – albeit marginal – in the following years. A relatively low risk
environment and a well establish healthcare sector, thanks to high government expenditure, coupled with
an aging population will aid in the recovery of the market. However, the country’s ever-growing healthcare
bills will increase the likelihood of the government implementing further cost-containment measures.
Headline Expenditure Projections
? Pharmaceuticals: EUR5.80bn (USD6.38bn) in 2015 to EUR5.80bn (USD6.20bn) in 2016; -0.1% in
local currency terms and -2.8% in US dollar terms. Forecast in line with last quarter.
• Healthcare: EUR74.29bn (USD81.72bn) in 2015 to EUR75.48bn (USD80.77bn) in 2016; +1.6% in local
currency terms and -1.2% in US dollar terms. Forecast unchanged from last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Netherlands 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Netherlands 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2014-2020) 30
Industry Risk Reward Index 31
Western Europe Risk/Reward Index 31
Netherlands Risk/Reward Index 36
Rewards 36
Risks 36
Regulatory Review 37
Intellectual Property Issues 40
Pricing Regime 40
Reimbursement Regime 42
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Netherlands 2010-2015) 48
Table: Healthcare Personnel (Netherlands 2010-2015) 48
Table: Healthcare Activity (Netherlands 2010-2015) 49
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 51
Table: Biosimilars Approved In The EU 54
Research & Development 55
Clinical Trials 56
Epidemiology 57
Competitive Landscape 60
Research-Based Industry 60
Table: Pharmaceutical Production, 1995-2010 (EUR '000s) 60
Generic Drugmakers 61
Table: Multinational Market Activity 62
Pharmaceutical Distribution 62
Pharmaceutical Retail Sector 63
Company Profile 66
DSM 66
GlaxoSmithKline 69
Merck & Co 71
Novartis 73
Pfizer 75
Pharming Group 77
Qiagen 80
Sanofi 83
Demographic Forecast 85
Demographic Outlook 85
Table: Population Headline Indicators (Netherlands 1990-2025) 86
Table: Key Population Ratios (Netherlands 1990-2025) 86
Table: Urban/Rural Population & Life Expectancy (Netherlands 1990-2025) 87
Table: Population By Age Group (Netherlands 1990-2025) 87
Table: Population By Age Group % (Netherlands 1990-2025) 88
Glossary 90
Methodology 92
Pharmaceutical Expenditure Forecast Model 92
Healthcare Expenditure Forecast Model 92
Notes On Methodology 93
Risk/Reward Index Methodology 94
Index Overview 95
Table: Pharmaceutical Risk/Reward Index Indicators 95
Indicator Weightings 96

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Netherlands 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Netherlands 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2014-2020)
Table: Healthcare Resources (Netherlands 2010-2015)
Table: Healthcare Personnel (Netherlands 2010-2015)
Table: Healthcare Activity (Netherlands 2010-2015)
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
Table: Biosimilars Approved In The EU
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
Table: Multinational Market Activity
Table: Population Headline Indicators (Netherlands 1990-2025)
Table: Key Population Ratios (Netherlands 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Netherlands 1990-2025)
Table: Population By Age Group (Netherlands 1990-2025)
Table: Population By Age Group % (Netherlands 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators